CTLA4 and hepatocellular carcinoma: More recently, another anti-CTLA-4 monoclonal antibody, tremelimumab, was approved as part of the STRIDE regimen, in which a single priming dose of tremelimumab is used in combination with repeated doses of durvalumab (anti-PD-L1 antibody) to treat unresectable hepatocellular carcinoma.